Details of the Drug

General Information of Drug (ID: DMSWYF5)

Drug Name
Quinine
Synonyms
Aflukin; Chinin; Chinine; Chininum; Conchinin; Conquinine; Quindan; Quinidex; Quinidine; Quinimax; Quinina; Quinineanhydrous; Quinora; Quniacridine; Chinin [German]; Kinder Quinina; QUININE MONO HCL; Quinine Dab; Quinine [BAN]; Quinine anhydrous; Quinine bisulfate; Quinine sulfate; Quinine sulphate; Quinoline alkaloid; LT00645788;Q0028; SB01652; Beta-Quinine; Cin-Quin; Coco-Quinine; IBS-L0034250; Kinder Quinina (TN); Legatrin (TN); Quinine (BAN); Quinine, Anhydrous; Quinine, polymers; Quinine, tannate; Biquinate (*Bisulfate heptathydrate*); Dentojel (*Bisulfate heptathydrate*); Quinamm (*2:1 Sulfate salt*), dihydrate; Quine (*2:1 Sulfate salt*, dihydrate); Quinsan (*2:1 Sulfate salt*), dihydrate; Alpha-(6-Methoxy-4-quinoyl)-5-vinyl-2-quinclidinemethanol; Cinchonan-9-ol, 6'-methoxy-, (8.alpha.,9R)-, sulfate; (+)-Quinidine; (-)-Quinine; (1R)-(6-Methoxyquinolin-4-yl)((1S,4S,5R)-5-vinylquinuclidin-2-yl)methanol; (3A,8A,9r)-6'-methoxycinchonan-9-ol; (5-ethenyl-1-azabicyclo[2.2.2]octan-2-yl)-(6-methoxyquinolin-4-yl)methanol; (8-alpha,9R)-6'-Methoxycinchonan-9-ol; (8.alpha.,9R)-6'-Methoxycinchonan-9-ol; (8S,9R)-6'-Methoxycinchonan-9-ol; (8S,9R)-Quinine; (9R)-6'-methoxy-8alpha-cinchonan-9-ol; (R)-(-)-Quinine, 6-methoxycinchonidine; (R)-(-)-quinine; (R)-(6-Methoxy-quinolin-4-yl)-((2S,5S)-5-vinyl-1-aza-bicyclo[2.2.2]oct-2-yl)-methanol; (R)-(6-methoxyquinolin-4-yl)((2S,4S,8R)-8-vinylquinuclidin-2-yl)methanol; (R)-[(2S,4R,5R)-5-ethenyl-1-azabicyclo[2.2.2]octan-2-yl]-(6-methoxyquinolin-4-yl)methanol; (R)-[(2S,4S,5R)-5-ethenyl-1-azabicyclo[2.2.2]octan-2-yl]-(6-methoxyquinolin-4-yl)methanol; (R)-[(2S,5R)-5-ethenyl-1-azabicyclo[2.2.2]octan-2-yl]-(6-methoxyquinolin-4-yl)methanol; (S)-(5-ethenyl-1-azabicyclo[2.2.2]octan-2-yl)-(6-methoxyquinolin-4-yl)methanol; (S)-[(2R,4R,5S)-5-ethenyl-1-azabicyclo[2.2.2]octan-2-yl]-(6-methoxyquinolin-4-yl)methanol; 6'-Methoxycinchonan-9-ol; 6'-Methoxycinchonidine; 6'-Methoxycinchonine; 6-Methoxycinchonine
Indication
Disease Entry ICD 11 Status REF
Malaria 1F40-1F45 Approved [1], [2]
Therapeutic Class
Antimalarials
Drug Type
Small molecular drug
Structure
3D MOL 2D MOL
#Ro5 Violations (Lipinski): 0 Molecular Weight (mw) 324.4
Topological Polar Surface Area (xlogp) 2.9
Rotatable Bond Count (rotbonds) 4
Hydrogen Bond Donor Count (hbonddonor) 1
Hydrogen Bond Acceptor Count (hbondacc) 4
ADMET Property
Absorption
The absorption of drug is 76 - 88% [3]
BDDCS Class
Biopharmaceutics Drug Disposition Classification System (BDDCS) Class 1: high solubility and high permeability [4]
Clearance
The apparent oral clearance of drug is 0.17 L/h/kg [5]
Elimination
12% of drug is excreted from urine in the unchanged form [4]
Half-life
The concentration or amount of drug in body reduced by one-half in 18 hours [6]
Metabolism
The drug is metabolized via the hepatic [3]
MRTD
The Maximum Recommended Therapeutic Dose (MRTD) of drug that ensured maximising efficacy and moderate side effect is 71.0697 micromolar/kg/day [7]
Unbound Fraction
The unbound fraction of drug in plasma is 0.3% [6]
Vd
The volume of distribution (Vd) of drug is 1.43 +/- 0.18 L/kg [5]
Water Solubility
The ability of drug to dissolve in water is measured as 111.1 mg/mL [4]
Chemical Identifiers
Formula
C20H24N2O2
IUPAC Name
(R)-[(2S,4S,5R)-5-ethenyl-1-azabicyclo[2.2.2]octan-2-yl]-(6-methoxyquinolin-4-yl)methanol
Canonical SMILES
COC1=CC2=C(C=CN=C2C=C1)[C@H]([C@@H]3C[C@@H]4CCN3C[C@@H]4C=C)O
InChI
InChI=1S/C20H24N2O2/c1-3-13-12-22-9-7-14(13)10-19(22)20(23)16-6-8-21-18-5-4-15(24-2)11-17(16)18/h3-6,8,11,13-14,19-20,23H,1,7,9-10,12H2,2H3/t13-,14-,19-,20+/m0/s1
InChIKey
LOUPRKONTZGTKE-WZBLMQSHSA-N
Cross-matching ID
PubChem CID
3034034
ChEBI ID
CHEBI:15854
CAS Number
72402-53-0
DrugBank ID
DB00468
TTD ID
D03DDR
VARIDT ID
DR00054
INTEDE ID
DR1385
ACDINA ID
D00577

Molecular Interaction Atlas of This Drug


Drug Therapeutic Target (DTT)
DTT Name DTT ID UniProt ID MOA REF
E3 ubiquitin-protein ligase COP1 (RFWD2) TT05DLS COP1_HUMAN Modulator [8]

Drug Transporter (DTP)
DTP Name DTP ID UniProt ID MOA REF
Na(+)/Cl(-) betaine/GABA transporter (SLC6A12) DTBPTJF S6A12_HUMAN Substrate [9]
Organic cation/carnitine transporter 1 (SLC22A4) DT2EG60 S22A4_HUMAN Substrate [10]
Organic cation/carnitine transporter 2 (SLC22A5) DT3HUVD S22A5_HUMAN Substrate [11]
Organic cation transporter 1 (SLC22A1) DTT79CX S22A1_HUMAN Substrate [12]
Organic cation transporter 2 (SLC22A2) DT9IDPW S22A2_HUMAN Substrate [13]
P-glycoprotein 1 (ABCB1) DTUGYRD MDR1_HUMAN Substrate [14]

Drug-Metabolizing Enzyme (DME)
DME Name DME ID UniProt ID MOA REF
Cytochrome P450 3A4 (CYP3A4) DE4LYSA CP3A4_HUMAN Substrate [15]
Cytochrome P450 2D6 (CYP2D6) DECB0K3 CP2D6_HUMAN Substrate [16]
Cytochrome P450 2C9 (CYP2C9) DE5IED8 CP2C9_HUMAN Substrate [17]
Mephenytoin 4-hydroxylase (CYP2C19) DEGTFWK CP2CJ_HUMAN Substrate [18]
Cytochrome P450 1A2 (CYP1A2) DEJGDUW CP1A2_HUMAN Substrate [19]
Cytochrome P450 3A5 (CYP3A5) DEIBDNY CP3A5_HUMAN Substrate [20]
Cytochrome P450 2C8 (CYP2C8) DES5XRU CP2C8_HUMAN Substrate [21]
Cytochrome P450 3A7 (CYP3A7) DERD86B CP3A7_HUMAN Substrate [20]
Molecular Interaction Atlas (MIA) Jump to Detail Molecular Interaction Atlas of This Drug

Drug-Drug Interaction (DDI) Information of This Drug

Coadministration of a Drug Treating the Same Disease as Quinine
DDI Drug Name DDI Drug ID Severity Mechanism Disease REF
Lumefantrine DM29GAD Major Increased risk of prolong QT interval by the combination of Quinine and Lumefantrine. Malaria [1F40-1F45] [116]
Halofantrine DMOMK1V Major Increased risk of prolong QT interval by the combination of Quinine and Halofantrine. Malaria [1F40-1F45] [117]
Chloroquine DMSI5CB Major Increased risk of prolong QT interval by the combination of Quinine and Chloroquine. Malaria [1F40-1F45] [118]
Hydroxychloroquine DMSIVND Major Increased risk of prolong QT interval by the combination of Quinine and Hydroxychloroquine. Malaria [1F40-1F45] [118]
Primaquine DMWQ16I Moderate Increased risk of prolong QT interval by the combination of Quinine and Primaquine. Malaria [1F40-1F45] [119]
Coadministration of a Drug Treating the Disease Different from Quinine (Comorbidity)
DDI Drug Name DDI Drug ID Severity Mechanism Comorbidity REF
Repaglinide DM5SXUV Moderate Increased risk of hypoglycemia by the combination of Quinine and Repaglinide. Acute diabete complication [5A2Y] [120]
Glibenclamide DM8JXPZ Moderate Increased risk of hypoglycemia by the combination of Quinine and Glibenclamide. Acute diabete complication [5A2Y] [120]
Tolazamide DMIHRNA Moderate Increased risk of hypoglycemia by the combination of Quinine and Tolazamide. Acute diabete complication [5A2Y] [120]
Nateglinide DMLK2QH Moderate Increased risk of hypoglycemia by the combination of Quinine and Nateglinide. Acute diabete complication [5A2Y] [120]
Insulin-glulisine DMQI0FU Moderate Increased risk of hypoglycemia by the combination of Quinine and Insulin-glulisine. Acute diabete complication [5A2Y] [120]
Insulin-aspart DMX7V28 Moderate Increased risk of hypoglycemia by the combination of Quinine and Insulin-aspart. Acute diabete complication [5A2Y] [121]
Glipizide DMZA5PQ Moderate Increased risk of hypoglycemia by the combination of Quinine and Glipizide. Acute diabete complication [5A2Y] [120]
Ivosidenib DM8S6T7 Major Increased risk of prolong QT interval by the combination of Quinine and Ivosidenib. Acute myeloid leukaemia [2A60] [122]
Midostaurin DMI6E0R Moderate Increased risk of prolong QT interval by the combination of Quinine and Midostaurin. Acute myeloid leukaemia [2A60] [119]
Idarubicin DMM0XGL Moderate Decreased clearance of Quinine due to the transporter inhibition by Idarubicin. Acute myeloid leukaemia [2A60] [123]
Daunorubicin DMQUSBT Moderate Decreased clearance of Quinine due to the transporter inhibition by Daunorubicin. Acute myeloid leukaemia [2A60] [123]
Arn-509 DMT81LZ Moderate Increased metabolism of Quinine caused by Arn-509 mediated induction of CYP450 enzyme. Acute myeloid leukaemia [2A60] [124]
Gilteritinib DMWQ4MZ Moderate Increased risk of prolong QT interval by the combination of Quinine and Gilteritinib. Acute myeloid leukaemia [2A60] [125]
Oliceridine DM6MDCF Moderate Increased risk of prolong QT interval by the combination of Quinine and Oliceridine. Acute pain [MG31] [119]
Mitotane DMU1GX0 Moderate Increased metabolism of Quinine caused by Mitotane mediated induction of CYP450 enzyme. Adrenal cancer [2D11] [124]
Galantamine DMEO794 Moderate Decreased metabolism of Quinine caused by Galantamine mediated inhibition of CYP450 enzyme. Alzheimer disease [8A20] [126]
Rivastigmine DMG629M Moderate Increased risk of ventricular arrhythmias by the combination of Quinine and Rivastigmine. Alzheimer disease [8A20] [119]
Donepezil DMIYG7Z Minor Decreased metabolism of Quinine caused by Donepezil mediated inhibition of CYP450 enzyme. Alzheimer disease [8A20] [127]
Metronidazole DMTIVEN Minor Increased risk of prolong QT interval by the combination of Quinine and Metronidazole. Amoebiasis [1A36] [116]
Ivabradine DM0L594 Major Increased risk of ventricular arrhythmias by the combination of Quinine and Ivabradine. Angina pectoris [BA40] [128]
Bepridil DM0RKS4 Major Increased risk of prolong QT interval by the combination of Quinine and Bepridil. Angina pectoris [BA40] [119]
Dronedarone DMA8FS5 Major Increased risk of prolong QT interval by the combination of Quinine and Dronedarone. Angina pectoris [BA40] [119]
Bedaquiline DM3906J Major Increased risk of prolong QT interval by the combination of Quinine and Bedaquiline. Antimicrobial drug resistance [MG50-MG52] [129]
Methylphenobarbital DMDSWAG Moderate Increased metabolism of Quinine caused by Methylphenobarbital mediated induction of CYP450 enzyme. Anxiety disorder [6B00-6B0Z] [124]
Hydroxyzine DMF8Y74 Moderate Increased risk of prolong QT interval by the combination of Quinine and Hydroxyzine. Anxiety disorder [6B00-6B0Z] [119]
Voriconazole DMAOL2S Moderate Decreased metabolism of Quinine caused by Voriconazole mediated inhibition of CYP450 enzyme. Aspergillosis [1F20] [116]
Posaconazole DMUL5EW Moderate Decreased metabolism of Quinine caused by Posaconazole mediated inhibition of CYP450 enzyme. Aspergillosis [1F20] [116]
Levalbuterol DM5YBO1 Moderate Increased risk of prolong QT interval by the combination of Quinine and Levalbuterol. Asthma [CA23] [130]
Terbutaline DMD4381 Moderate Increased risk of ventricular arrhythmias by the combination of Quinine and Terbutaline. Asthma [CA23] [131]
Pirbuterol DMI5678 Moderate Increased risk of prolong QT interval by the combination of Quinine and Pirbuterol. Asthma [CA23] [131]
Salbutamol DMN9CWF Moderate Increased risk of prolong QT interval by the combination of Quinine and Salbutamol. Asthma [CA23] [130]
Formoterol DMSOURV Moderate Increased risk of prolong QT interval by the combination of Quinine and Formoterol. Asthma [CA23] [131]
Lisdexamfetamine DM6W8V5 Moderate Increased risk of prolong QT interval by the combination of Quinine and Lisdexamfetamine. Attention deficit hyperactivity disorder [6A05] [128]
Desipramine DMT2FDC Moderate Increased risk of prolong QT interval by the combination of Quinine and Desipramine. Attention deficit hyperactivity disorder [6A05] [119]
Ofloxacin DM0VQN3 Moderate Increased risk of prolong QT interval by the combination of Quinine and Ofloxacin. Bacterial infection [1A00-1C4Z] [132]
Ciprofloxacin XR DM2NLS9 Moderate Increased risk of prolong QT interval by the combination of Quinine and Ciprofloxacin XR. Bacterial infection [1A00-1C4Z] [119]
Dalfopristin DM4LTKV Moderate Decreased metabolism of Quinine caused by Dalfopristin mediated inhibition of CYP450 enzyme. Bacterial infection [1A00-1C4Z] [116]
Clarithromycin DM4M1SG Major Decreased metabolism of Quinine caused by Clarithromycin mediated inhibition of CYP450 enzyme. Bacterial infection [1A00-1C4Z] [133]
Sulfamethoxazole DMB08GE Minor Increased risk of prolong QT interval by the combination of Quinine and Sulfamethoxazole. Bacterial infection [1A00-1C4Z] [119]
Sparfloxacin DMB4HCT Major Increased risk of prolong QT interval by the combination of Quinine and Sparfloxacin. Bacterial infection [1A00-1C4Z] [132]
Gemifloxacin DMHT34O Moderate Increased risk of prolong QT interval by the combination of Quinine and Gemifloxacin. Bacterial infection [1A00-1C4Z] [132]
Levofloxacin DMS60RB Moderate Increased risk of prolong QT interval by the combination of Quinine and Levofloxacin. Bacterial infection [1A00-1C4Z] [132]
Troleandomycin DMUZNIG Major Decreased metabolism of Quinine caused by Troleandomycin mediated inhibition of CYP450 enzyme. Bacterial infection [1A00-1C4Z] [133]
Lomefloxacin DMVRH9C Moderate Increased risk of prolong QT interval by the combination of Quinine and Lomefloxacin. Bacterial infection [1A00-1C4Z] [119]
Telithromycin DMZ4P3A Major Decreased metabolism of Quinine caused by Telithromycin mediated inhibition of CYP450 enzyme. Bacterial infection [1A00-1C4Z] [133]
Tetracycline DMZA017 Minor Decreased metabolism of Quinine caused by Tetracycline mediated inhibition of CYP450 enzyme. Bacterial infection [1A00-1C4Z] [134]
Retigabine DMGNYIH Moderate Increased risk of prolong QT interval by the combination of Quinine and Retigabine. Behcet disease [4A62] [119]
Pexidartinib DMS2J0Z Moderate Increased metabolism of Quinine caused by Pexidartinib mediated induction of CYP450 enzyme. Bone/articular cartilage neoplasm [2F7B] [124]
Loperamide DMOJZQ9 Major Increased risk of prolong QT interval by the combination of Quinine and Loperamide. Bowel habit change [ME05] [135]
Eribulin DM1DX4Q Moderate Increased risk of prolong QT interval by the combination of Quinine and Eribulin. Breast cancer [2C60-2C6Y] [119]
Talazoparib DM1KS78 Moderate Decreased clearance of Quinine due to the transporter inhibition by Talazoparib. Breast cancer [2C60-2C6Y] [136]
Lapatinib DM3BH1Y Moderate Increased risk of prolong QT interval by the combination of Quinine and Lapatinib. Breast cancer [2C60-2C6Y] [119]
Tucatinib DMBESUA Moderate Decreased metabolism of Quinine caused by Tucatinib mediated inhibition of CYP450 enzyme. Breast cancer [2C60-2C6Y] [116]
Toremifene DMQYUWG Major Increased risk of prolong QT interval by the combination of Quinine and Toremifene. Breast cancer [2C60-2C6Y] [119]
Bosutinib DMTI8YE Moderate Decreased clearance of Quinine due to the transporter inhibition by Bosutinib. Breast cancer [2C60-2C6Y] [128]
Sotalol DML60TN Major Increased risk of prolong QT interval by the combination of Quinine and Sotalol. Cardiac arrhythmia [BC9Z] [119]
PF-04449913 DMSB068 Moderate Increased risk of prolong QT interval by the combination of Quinine and PF-04449913. Chronic myelomonocytic leukaemia [2A40] [137]
Olodaterol DM62B78 Moderate Increased risk of prolong QT interval by the combination of Quinine and Olodaterol. Chronic obstructive pulmonary disease [CA22] [131]
Vilanterol DMF5EK1 Moderate Increased risk of prolong QT interval by the combination of Quinine and Vilanterol. Chronic obstructive pulmonary disease [CA22] [130]
Salmeterol DMIEU69 Moderate Increased risk of ventricular arrhythmias by the combination of Quinine and Salmeterol. Chronic obstructive pulmonary disease [CA22] [131]
Indacaterol DMQJHR7 Moderate Increased risk of ventricular arrhythmias by the combination of Quinine and Indacaterol. Chronic obstructive pulmonary disease [CA22] [131]
Arformoterol DMYM974 Moderate Increased risk of prolong QT interval by the combination of Quinine and Arformoterol. Chronic obstructive pulmonary disease [CA22] [131]
Phenylbutazone DMAYL0T Moderate Increased metabolism of Quinine caused by Phenylbutazone mediated induction of CYP450 enzyme. Chronic pain [MG30] [124]
Fidaxomicin DMFP6MV Minor Decreased clearance of Quinine due to the transporter inhibition by Fidaxomicin. Clostridium difficile enterocolitis [1A04] [138]
Oxaliplatin DMQNWRD Moderate Increased risk of prolong QT interval by the combination of Quinine and Oxaliplatin. Colorectal cancer [2B91] [119]
Isoproterenol DMK7MEY Moderate Increased risk of prolong QT interval by the combination of Quinine and Isoproterenol. Conduction disorder [BC63] [130]
Halothane DM80OZ5 Moderate Increased risk of prolong QT interval by the combination of Quinine and Halothane. Corneal disease [9A76-9A78] [119]
Propofol DMB4OLE Moderate Increased risk of prolong QT interval by the combination of Quinine and Propofol. Corneal disease [9A76-9A78] [139]
Sevoflurane DMC9O43 Moderate Increased risk of prolong QT interval by the combination of Quinine and Sevoflurane. Corneal disease [9A76-9A78] [119]
Probucol DMVZQ2M Moderate Increased risk of prolong QT interval by the combination of Quinine and Probucol. Coronary atherosclerosis [BA80] [119]
Dextromethorphan DMUDJZM Moderate Decreased metabolism of Quinine caused by Dextromethorphan mediated inhibition of CYP450 enzyme. Cough [MD12] [116]
Clofazimine DMEBOFW Moderate Increased risk of prolong QT interval by the combination of Quinine and Clofazimine. Crohn disease [DD70] [140]
Mifepristone DMGZQEF Major Increased risk of prolong QT interval by the combination of Quinine and Mifepristone. Cushing syndrome [5A70] [119]
Pasireotide DMHM7JS Major Increased risk of prolong QT interval by the combination of Quinine and Pasireotide. Cushing syndrome [5A70] [119]
Osilodrostat DMIJC9X Moderate Increased risk of prolong QT interval by the combination of Quinine and Osilodrostat. Cushing syndrome [5A70] [128]
Lumacaftor DMCLWDJ Moderate Increased metabolism of Quinine caused by Lumacaftor mediated induction of CYP450 enzyme. Cystic fibrosis [CA25] [124]
MK-8228 DMOB58Q Moderate Decreased metabolism of Quinine caused by MK-8228 mediated inhibition of CYP450 enzyme. Cytomegaloviral disease [1D82] [116]
Rivaroxaban DMQMBZ1 Moderate Decreased clearance of Quinine due to the transporter inhibition by Rivaroxaban. Deep vein thrombosis [BD71] [141]
Sertraline DM0FB1J Moderate Increased risk of prolong QT interval by the combination of Quinine and Sertraline. Depression [6A70-6A7Z] [119]
Trimipramine DM1SC8M Moderate Increased risk of prolong QT interval by the combination of Quinine and Trimipramine. Depression [6A70-6A7Z] [119]
Fluoxetine DM3PD2C Moderate Increased risk of prolong QT interval by the combination of Quinine and Fluoxetine. Depression [6A70-6A7Z] [119]
Nortriptyline DM4KDYJ Moderate Increased risk of prolong QT interval by the combination of Quinine and Nortriptyline. Depression [6A70-6A7Z] [119]
Nefazodone DM4ZS8M Moderate Decreased metabolism of Quinine caused by Nefazodone mediated inhibition of CYP450 enzyme. Depression [6A70-6A7Z] [116]
Duloxetine DM9BI7M Moderate Decreased metabolism of Quinine caused by Duloxetine mediated inhibition of CYP450 enzyme. Depression [6A70-6A7Z] [142]
Escitalopram DMFK9HG Major Increased risk of prolong QT interval by the combination of Quinine and Escitalopram. Depression [6A70-6A7Z] [119]
Clomipramine DMINRKW Moderate Increased risk of prolong QT interval by the combination of Quinine and Clomipramine. Depression [6A70-6A7Z] [119]
Trazodone DMK1GBJ Moderate Increased risk of prolong QT interval by the combination of Quinine and Trazodone. Depression [6A70-6A7Z] [143]
Amoxapine DMKITQE Moderate Increased risk of prolong QT interval by the combination of Quinine and Amoxapine. Depression [6A70-6A7Z] [119]
Maprotiline DMPWB7T Moderate Increased risk of prolong QT interval by the combination of Quinine and Maprotiline. Depression [6A70-6A7Z] [119]
Tetrabenazine DMYWQ0O Moderate Increased risk of prolong QT interval by the combination of Quinine and Tetrabenazine. Dissociative neurological symptom disorder [6B60] [119]
Deutetrabenazine DMUPFLI Moderate Additive CNS depression effects by the combination of Quinine and Deutetrabenazine. Dystonic disorder [8A02] [144]
Ingrezza DMVPLNC Moderate Additive CNS depression effects by the combination of Quinine and Ingrezza. Dystonic disorder [8A02] [145]
Primidone DM0WX6I Moderate Increased metabolism of Quinine caused by Primidone mediated induction of CYP450 enzyme. Epilepsy/seizure [8A61-8A6Z] [124]
Felbamate DM1V5ZS Moderate Increased metabolism of Quinine caused by Felbamate mediated induction of CYP450 enzyme. Epilepsy/seizure [8A61-8A6Z] [124]
Oxcarbazepine DM5PU6O Moderate Increased metabolism of Quinine caused by Oxcarbazepine mediated induction of CYP450 enzyme. Epilepsy/seizure [8A61-8A6Z] [124]
Cenobamate DMGOVHA Moderate Increased metabolism of Quinine caused by Cenobamate mediated induction of CYP450 enzyme. Epilepsy/seizure [8A61-8A6Z] [124]
Fosphenytoin DMOX3LB Moderate Increased metabolism of Quinine caused by Fosphenytoin mediated induction of CYP450 enzyme. Epilepsy/seizure [8A61-8A6Z] [124]
Rufinamide DMWE60C Moderate Increased metabolism of Quinine caused by Rufinamide mediated induction of CYP450 enzyme. Epilepsy/seizure [8A61-8A6Z] [124]
Phenobarbital DMXZOCG Moderate Increased metabolism of Quinine caused by Phenobarbital mediated induction of CYP450 enzyme. Epilepsy/seizure [8A61-8A6Z] [146]
Carbamazepine DMZOLBI Moderate Increased metabolism of Quinine caused by Carbamazepine mediated induction of CYP450 enzyme. Epilepsy/seizure [8A61-8A6Z] [146]
Tazemetostat DMWP1BH Moderate Increased metabolism of Quinine caused by Tazemetostat mediated induction of CYP450 enzyme. Follicular lymphoma [2A80] [124]
Solifenacin DMG592Q Moderate Increased risk of prolong QT interval by the combination of Quinine and Solifenacin. Functional bladder disorder [GC50] [119]
Tolterodine DMSHPW8 Minor Decreased metabolism of Quinine caused by Tolterodine mediated inhibition of CYP450 enzyme. Functional bladder disorder [GC50] [147]
Darifenacin DMWXLYZ Moderate Decreased metabolism of Quinine caused by Darifenacin mediated inhibition of CYP450 enzyme. Functional bladder disorder [GC50] [148]
Itraconazole DMCR1MV Moderate Decreased metabolism of Quinine caused by Itraconazole mediated inhibition of CYP450 enzyme. Fungal infection [1F29-1F2F] [116]
Pentamidine DMHZJCG Moderate Increased risk of prolong QT interval by the combination of Quinine and Pentamidine. Fungal infection [1F29-1F2F] [119]
Miconazole DMPMYE8 Moderate Decreased metabolism of Quinine caused by Miconazole mediated inhibition of CYP450 enzyme. Fungal infection [1F29-1F2F] [116]
Ketoconazole DMPZI3Q Moderate Decreased metabolism of Quinine caused by Ketoconazole mediated inhibition of CYP450 enzyme. Fungal infection [1F29-1F2F] [116]
Cisapride DMY7PED Major Increased risk of prolong QT interval by the combination of Quinine and Cisapride. Gastro-oesophageal reflux disease [DA22] [119]
Ripretinib DM958QB Moderate Decreased clearance of Quinine due to the transporter inhibition by Ripretinib. Gastrointestinal stromal tumour [2B5B] [116]
Sunitinib DMCBJSR Moderate Increased risk of prolong QT interval by the combination of Quinine and Sunitinib. Gastrointestinal stromal tumour [2B5B] [119]
Boceprevir DMBSHMF Moderate Decreased metabolism of Quinine caused by Boceprevir mediated inhibition of CYP450 enzyme. Hepatitis virus infection [1E50-1E51] [116]
Telaprevir DMMRV29 Moderate Decreased metabolism of Quinine caused by Telaprevir mediated inhibition of CYP450 enzyme. Hepatitis virus infection [1E50-1E51] [116]
Rifampin DMA8J1G Major Increased metabolism of Quinine caused by Rifampin mediated induction of CYP450 enzyme. HIV-infected patients with tuberculosis [1B10-1B14] [149]
Rifapentine DMCHV4I Moderate Increased metabolism of Quinine caused by Rifapentine mediated induction of CYP450 enzyme. HIV-infected patients with tuberculosis [1B10-1B14] [124]
Brentuximab vedotin DMWLC57 Moderate Decreased clearance of Quinine due to the transporter inhibition by Brentuximab vedotin. Hodgkin lymphoma [2B30] [150]
Delavirdine DM3NF5G Moderate Decreased metabolism of Quinine caused by Delavirdine mediated inhibition of CYP450 enzyme. Human immunodeficiency virus disease [1C60-1C62] [116]
Fosamprenavir DM4W9B3 Moderate Decreased metabolism of Quinine caused by Fosamprenavir mediated inhibition of CYP450 enzyme. Human immunodeficiency virus disease [1C60-1C62] [116]
Fostemsavir DM50ILT Moderate Increased risk of prolong QT interval by the combination of Quinine and Fostemsavir. Human immunodeficiency virus disease [1C60-1C62] [151]
Cobicistat DM6L4H2 Moderate Decreased metabolism of Quinine caused by Cobicistat mediated inhibition of CYP450 enzyme. Human immunodeficiency virus disease [1C60-1C62] [116]
Efavirenz DMC0GSJ Major Increased risk of prolong QT interval by the combination of Quinine and Efavirenz. Human immunodeficiency virus disease [1C60-1C62] [152]
Saquinavir DMG814N Major Increased risk of prolong QT interval by the combination of Quinine and Saquinavir. Human immunodeficiency virus disease [1C60-1C62] [153]
Etravirine DMGV8QU Moderate Increased metabolism of Quinine caused by Etravirine mediated induction of CYP450 enzyme. Human immunodeficiency virus disease [1C60-1C62] [124]
Rilpivirine DMJ0QOW Moderate Increased risk of prolong QT interval by the combination of Quinine and Rilpivirine. Human immunodeficiency virus disease [1C60-1C62] [119]
Amprenavir DMLMXE0 Moderate Decreased metabolism of Quinine caused by Amprenavir mediated inhibition of CYP450 enzyme. Human immunodeficiency virus disease [1C60-1C62] [116]
Darunavir DMN3GCH Moderate Decreased metabolism of Quinine caused by Darunavir mediated inhibition of CYP450 enzyme. Human immunodeficiency virus disease [1C60-1C62] [116]
Atazanavir DMSYRBX Moderate Decreased metabolism of Quinine caused by Atazanavir mediated inhibition of CYP450 enzyme. Human immunodeficiency virus disease [1C60-1C62] [116]
Ritonavir DMU764S Major Decreased metabolism of Quinine caused by Ritonavir mediated inhibition of CYP450 enzyme. Human immunodeficiency virus disease [1C60-1C62] [154]
Aliskiren DM1BV7W Moderate Decreased clearance of Quinine due to the transporter inhibition by Aliskiren. Hypertension [BA00-BA04] [119]
Verapamil DMA7PEW Moderate Decreased metabolism of Quinine caused by Verapamil mediated inhibition of CYP450 enzyme. Hypertension [BA00-BA04] [116]
Conivaptan DM1V329 Moderate Decreased metabolism of Quinine caused by Conivaptan mediated inhibition of CYP450 enzyme. Hypo-osmolality/hyponatraemia [5C72] [116]
Tolvaptan DMIWFRL Moderate Decreased clearance of Quinine due to the transporter inhibition by Tolvaptan. Hypo-osmolality/hyponatraemia [5C72] [155]
Berotralstat DMWA2DZ Major Decreased clearance of Quinine due to the transporter inhibition by Berotralstat. Innate/adaptive immunodeficiency [4A00] [156]
Amobarbital DM0GQ8N Moderate Increased metabolism of Quinine caused by Amobarbital mediated induction of CYP450 enzyme. Insomnia [7A00-7A0Z] [124]
Polyethylene glycol DM4I1JP Major Increased risk of ventricular arrhythmias by the combination of Quinine and Polyethylene glycol. Irritable bowel syndrome [DD91] [157]
Phenolphthalein DM5SICT Moderate Increased risk of ventricular arrhythmias by the combination of Quinine and Phenolphthalein. Irritable bowel syndrome [DD91] [119]
Naloxegol DML0B41 Minor Decreased metabolism of Quinine caused by Naloxegol mediated inhibition of CYP450 enzyme. Large intestine motility disorder [DB32] [158]
Crizotinib DM4F29C Major Increased risk of prolong QT interval by the combination of Quinine and Crizotinib. Lung cancer [2C25] [159]
Brigatinib DM7W94S Moderate Increased metabolism of Quinine caused by Brigatinib mediated induction of CYP450 enzyme. Lung cancer [2C25] [160]
Porfimer Sodium DM7ZWNY Moderate Increased risk of photosensitivity reactions by the combination of Quinine and Porfimer Sodium. Lung cancer [2C25] [161]
Ceritinib DMB920Z Major Increased risk of prolong QT interval by the combination of Quinine and Ceritinib. Lung cancer [2C25] [119]
PF-06463922 DMKM7EW Moderate Increased metabolism of Quinine caused by PF-06463922 mediated induction of CYP450 enzyme. Lung cancer [2C25] [124]
Osimertinib DMRJLAT Major Increased risk of prolong QT interval by the combination of Quinine and Osimertinib. Lung cancer [2C25] [162]
Selpercatinib DMZR15V Major Increased risk of prolong QT interval by the combination of Quinine and Selpercatinib. Lung cancer [2C25] [128]
Inotuzumab ozogamicin DMAC130 Moderate Increased risk of prolong QT interval by the combination of Quinine and Inotuzumab ozogamicin. Malignant haematopoietic neoplasm [2B33] [128]
Idelalisib DM602WT Moderate Decreased metabolism of Quinine caused by Idelalisib mediated inhibition of CYP450 enzyme. Mature B-cell leukaemia [2A82] [163]
GDC-0199 DMH0QKA Major Decreased clearance of Quinine due to the transporter inhibition by GDC-0199. Mature B-cell leukaemia [2A82] [116]
IPI-145 DMWA24P Moderate Decreased metabolism of Quinine caused by IPI-145 mediated inhibition of CYP450 enzyme. Mature B-cell leukaemia [2A82] [116]
Arsenic trioxide DM61TA4 Major Increased risk of prolong QT interval by the combination of Quinine and Arsenic trioxide. Mature B-cell lymphoma [2A85] [164]
Arry-162 DM1P6FR Moderate Decreased clearance of Quinine due to the transporter inhibition by Arry-162. Melanoma [2C30] [116]
Vemurafenib DM62UG5 Major Increased risk of prolong QT interval by the combination of Quinine and Vemurafenib. Melanoma [2C30] [119]
LGX818 DMNQXV8 Moderate Increased risk of prolong QT interval by the combination of Quinine and LGX818. Melanoma [2C30] [165]
Dabrafenib DMX6OE3 Moderate Increased metabolism of Quinine caused by Dabrafenib mediated induction of CYP450 enzyme. Melanoma [2C30] [124]
Ubrogepant DM749I3 Moderate Decreased clearance of Quinine due to the transporter inhibition by Ubrogepant. Migraine [8A80] [166]
Exjade DMHPRWG Moderate Decreased metabolism of Quinine caused by Exjade mediated inhibition of CYP450 enzyme. Mineral absorption/transport disorder [5C64] [167]
Panobinostat DM58WKG Major Increased risk of prolong QT interval by the combination of Quinine and Panobinostat. Multiple myeloma [2A83] [168]
Thalidomide DM70BU5 Moderate Increased risk of ventricular arrhythmias by the combination of Quinine and Thalidomide. Multiple myeloma [2A83] [116]
Siponimod DM2R86O Major Increased risk of ventricular arrhythmias by the combination of Quinine and Siponimod. Multiple sclerosis [8A40] [116]
Fingolimod DM5JVAN Major Increased risk of ventricular arrhythmias by the combination of Quinine and Fingolimod. Multiple sclerosis [8A40] [119]
Ozanimod DMT6AM2 Major Increased risk of ventricular arrhythmias by the combination of Quinine and Ozanimod. Multiple sclerosis [8A40] [169]
Rifabutin DM1YBHK Moderate Increased metabolism of Quinine caused by Rifabutin mediated induction of CYP450 enzyme. Mycobacterium infection [1B10-1B21] [124]
Fedratinib DM4ZBK6 Moderate Decreased metabolism of Quinine caused by Fedratinib mediated inhibition of CYP450 enzyme. Myeloproliferative neoplasm [2A20] [116]
Dasatinib DMJV2EK Moderate Increased risk of prolong QT interval by the combination of Quinine and Dasatinib. Myeloproliferative neoplasm [2A20] [170]
Modafinil DMYILBE Minor Increased metabolism of Quinine caused by Modafinil mediated induction of CYP450 enzyme. Narcolepsy [7A20] [171]
Promethazine DM6I5GR Moderate Increased risk of prolong QT interval by the combination of Quinine and Promethazine. Nausea/vomiting [MD90] [119]
Granisetron DMIUW25 Moderate Increased risk of prolong QT interval by the combination of Quinine and Granisetron. Nausea/vomiting [MD90] [119]
Ondansetron DMOTQ1I Moderate Increased risk of prolong QT interval by the combination of Quinine and Ondansetron. Nausea/vomiting [MD90] [119]
Entrectinib DMMPTLH Moderate Increased risk of prolong QT interval by the combination of Quinine and Entrectinib. Non-small cell lung cancer [2C25] [116]
Levomethadyl Acetate DM06HG5 Major Increased risk of prolong QT interval by the combination of Quinine and Levomethadyl Acetate. Opioid use disorder [6C43] [128]
Lofexidine DM1WXA6 Moderate Increased risk of prolong QT interval by the combination of Quinine and Lofexidine. Opioid use disorder [6C43] [119]
S-297995 DM26IH8 Moderate Decreased metabolism of Quinine caused by S-297995 mediated inhibition of CYP450 enzyme. Opioid use disorder [6C43] [128]
Rucaparib DM9PVX8 Moderate Increased risk of prolong QT interval by the combination of Quinine and Rucaparib. Ovarian cancer [2C73] [119]
MK-4827 DMLYGH4 Moderate Decreased clearance of Quinine due to the transporter inhibition by MK-4827. Ovarian cancer [2C73] [172]
Dextropropoxyphene DM23HCX Moderate Increased risk of prolong QT interval by the combination of Quinine and Dextropropoxyphene. Pain [MG30-MG3Z] [173]
Prilocaine DMI7DZ2 Major Increased risk of methemoglobinemia by the combination of Quinine and Prilocaine. Pain [MG30-MG3Z] [174]
Buprenorphine DMPRI8G Moderate Increased risk of prolong QT interval by the combination of Quinine and Buprenorphine. Pain [MG30-MG3Z] [119]
Triclabendazole DMPWGBR Moderate Increased risk of prolong QT interval by the combination of Quinine and Triclabendazole. Parasitic worm infestation [1F90] [119]
Pimavanserin DMR7IVC Moderate Increased risk of prolong QT interval by the combination of Quinine and Pimavanserin. Parkinsonism [8A00] [175]
Abametapir DM2RX0I Moderate Decreased metabolism of Quinine caused by Abametapir mediated inhibition of CYP450 enzyme. Pediculosis [1G00] [176]
Famotidine DMRL3AB Moderate Increased risk of prolong QT interval by the combination of Quinine and Famotidine. Peptic ulcer [DA61] [116]
Macimorelin DMQYJIR Major Increased risk of prolong QT interval by the combination of Quinine and Macimorelin. Pituitary gland disorder [5A60-5A61] [177]
Lefamulin DME6G97 Major Increased risk of prolong QT interval by the combination of Quinine and Lefamulin. Pneumonia [CA40] [178]
Lonafarnib DMGM2Z6 Moderate Decreased metabolism of Quinine caused by Lonafarnib mediated inhibition of CYP450 enzyme. Premature ageing appearance [LD2B] [116]
Ritodrine DM4V6RL Moderate Increased risk of prolong QT interval by the combination of Quinine and Ritodrine. Preterm labour/delivery [JB00] [131]
Degarelix DM3O8QY Moderate Increased risk of prolong QT interval by the combination of Quinine and Degarelix. Prostate cancer [2C82] [128]
ABIRATERONE DM8V75C Moderate Increased risk of prolong QT interval by the combination of Quinine and ABIRATERONE. Prostate cancer [2C82] [128]
Nilutamide DMFN07X Moderate Increased risk of prolong QT interval by the combination of Quinine and Nilutamide. Prostate cancer [2C82] [128]
Enzalutamide DMGL19D Moderate Increased metabolism of Quinine caused by Enzalutamide mediated induction of CYP450 enzyme. Prostate cancer [2C82] [124]
Flutamide DMK0O7U Moderate Increased risk of prolong QT interval by the combination of Quinine and Flutamide. Prostate cancer [2C82] [128]
Relugolix DMK7IWL Major Decreased metabolism of Quinine caused by Relugolix mediated inhibition of CYP450 enzyme. Prostate cancer [2C82] [179]
Bicalutamide DMZMSPF Moderate Increased risk of prolong QT interval by the combination of Quinine and Bicalutamide. Prostate cancer [2C82] [128]
Silodosin DMJSBT6 Moderate Decreased clearance of Quinine due to the transporter inhibition by Silodosin. Prostate hyperplasia [GA90] [180]
Levomepromazine DMIKFEL Moderate Increased risk of prolong QT interval by the combination of Quinine and Levomepromazine. Psychotic disorder [6A20-6A25] [119]
Fluphenazine DMIT8LX Moderate Increased risk of prolong QT interval by the combination of Quinine and Fluphenazine. Psychotic disorder [6A20-6A25] [119]
Triflupromazine DMKFQJP Moderate Increased risk of prolong QT interval by the combination of Quinine and Triflupromazine. Psychotic disorder [6A20-6A25] [119]
Bosentan DMIOGBU Moderate Increased metabolism of Quinine caused by Bosentan mediated induction of CYP450 enzyme. Pulmonary hypertension [BB01] [124]
Riociguat DMXBLMP Moderate Decreased clearance of Quinine due to the transporter inhibition by Riociguat. Pulmonary hypertension [BB01] [116]
Temsirolimus DMS104F Moderate Increased plasma concentrations of Quinine and Temsirolimus due to competitive inhibition of the same metabolic pathway. Renal cell carcinoma [2C90] [181]
Gatifloxacin DMSL679 Major Increased risk of prolong QT interval by the combination of Quinine and Gatifloxacin. Respiratory infection [CA07-CA4Z] [182]
Dexamethasone DMMWZET Moderate Increased metabolism of Quinine caused by Dexamethasone mediated induction of CYP450 enzyme. Rheumatoid arthritis [FA20] [124]
Nafcillin DMN9RPO Moderate Increased metabolism of Quinine caused by Nafcillin mediated induction of CYP450 enzyme. Rheumatoid arthritis [FA20] [124]
Quetiapine DM1N62C Moderate Increased risk of prolong QT interval by the combination of Quinine and Quetiapine. Schizophrenia [6A20] [119]
Mesoridazine DM2ZGAN Major Increased risk of prolong QT interval by the combination of Quinine and Mesoridazine. Schizophrenia [6A20] [119]
Thioridazine DM35M8J Major Decreased metabolism of Quinine caused by Thioridazine mediated inhibition of CYP450 enzyme. Schizophrenia [6A20] [183]
Aripiprazole DM3NUMH Moderate Decreased metabolism of Quinine caused by Aripiprazole mediated inhibition of CYP450 enzyme. Schizophrenia [6A20] [184]
Iloperidone DM6AUFY Major Increased risk of prolong QT interval by the combination of Quinine and Iloperidone. Schizophrenia [6A20] [119]
Paliperidone DM7NPJS Moderate Increased risk of prolong QT interval by the combination of Quinine and Paliperidone. Schizophrenia [6A20] [119]
Haloperidol DM96SE0 Major Increased risk of prolong QT interval by the combination of Quinine and Haloperidol. Schizophrenia [6A20] [119]
Perphenazine DMA4MRX Moderate Increased risk of prolong QT interval by the combination of Quinine and Perphenazine. Schizophrenia [6A20] [119]
Chlorpromazine DMBGZI3 Moderate Increased risk of prolong QT interval by the combination of Quinine and Chlorpromazine. Schizophrenia [6A20] [119]
Trifluoperazine DMKBYWI Moderate Increased risk of prolong QT interval by the combination of Quinine and Trifluoperazine. Schizophrenia [6A20] [119]
Risperidone DMN6DXL Moderate Increased risk of prolong QT interval by the combination of Quinine and Risperidone. Schizophrenia [6A20] [119]
Amisulpride DMSJVAM Major Increased risk of prolong QT interval by the combination of Quinine and Amisulpride. Schizophrenia [6A20] [185]
Asenapine DMSQZE2 Moderate Increased risk of prolong QT interval by the combination of Quinine and Asenapine. Schizophrenia [6A20] [119]
Vardenafil DMTBGW8 Moderate Increased risk of prolong QT interval by the combination of Quinine and Vardenafil. Sexual dysfunction [HA00-HA01] [119]
Voxelotor DMCS6M5 Moderate Decreased metabolism of Quinine caused by Voxelotor mediated inhibition of CYP450 enzyme. Sickle-cell disorder [3A51] [116]
Telotristat ethyl DMDIYFZ Moderate Increased metabolism of Quinine caused by Telotristat ethyl mediated induction of CYP450 enzyme. Small intestine developmental anomaly [DA90] [128]
Larotrectinib DM26CQR Moderate Decreased metabolism of Quinine caused by Larotrectinib mediated inhibition of CYP450 enzyme. Solid tumour/cancer [2A00-2F9Z] [116]
Docetaxel DMDI269 Moderate Decreased clearance of Quinine due to the transporter inhibition by Docetaxel. Solid tumour/cancer [2A00-2F9Z] [186]
Armodafinil DMGB035 Minor Increased metabolism of Quinine caused by Armodafinil mediated induction of CYP450 enzyme. Solid tumour/cancer [2A00-2F9Z] [171]
LEE011 DMMX75K Major Decreased metabolism of Quinine caused by LEE011 mediated inhibition of CYP450 enzyme. Solid tumour/cancer [2A00-2F9Z] [119]
Vandetanib DMRICNP Major Increased risk of prolong QT interval by the combination of Quinine and Vandetanib. Solid tumour/cancer [2A00-2F9Z] [119]
Triptorelin DMTK4LS Moderate Increased risk of prolong QT interval by the combination of Quinine and Triptorelin. Solid tumour/cancer [2A00-2F9Z] [128]
Taxol DMUOT9V Moderate Decreased clearance of Quinine due to the transporter inhibition by Taxol. Solid tumour/cancer [2A00-2F9Z] [186]
Doxorubicin DMVP5YE Moderate Increased risk of prolong QT interval by the combination of Quinine and Doxorubicin. Solid tumour/cancer [2A00-2F9Z] [119]
Telavancin DM58VQX Moderate Increased risk of prolong QT interval by the combination of Quinine and Telavancin. Staphylococcal/streptococcal disease [1B5Y] [119]
Adenosine DMM2NSK Major Increased risk of ventricular arrhythmias by the combination of Quinine and Adenosine. Supraventricular tachyarrhythmia [BC81] [187]
Pomalidomide DMTGBAX Moderate Decreased clearance of Quinine due to the transporter inhibition by Pomalidomide. Systemic sclerosis [4A42] [116]
Fostamatinib DM6AUHV Moderate Decreased clearance of Quinine due to the transporter inhibition by Fostamatinib. Thrombocytopenia [3B64] [188]
Lusutrombopag DMH6IKO Moderate Decreased clearance of Quinine due to the transporter inhibition by Lusutrombopag. Thrombocytopenia [3B64] [189]
Apixaban DM89JLN Moderate Decreased clearance of Quinine due to the transporter inhibition by Apixaban. Thrombosis [DB61-GB90] [128]
Lenvatinib DMB1IU4 Moderate Increased risk of prolong QT interval by the combination of Quinine and Lenvatinib. Thyroid cancer [2D10] [119]
Papaverine DMCA9QP Major Increased risk of prolong QT interval by the combination of Quinine and Papaverine. Tonus and reflex abnormality [MB47] [190]
Tizanidine DMR2IQ4 Moderate Increased risk of prolong QT interval by the combination of Quinine and Tizanidine. Tonus and reflex abnormality [MB47] [119]
Sirolimus DMGW1ID Moderate Increased plasma concentrations of Quinine and Sirolimus due to competitive inhibition of the same metabolic pathway. Transplant rejection [NE84] [181]
Tacrolimus DMZ7XNQ Moderate Increased plasma concentrations of Quinine and Tacrolimus due to competitive inhibition of the same metabolic pathway. Transplant rejection [NE84] [181]
Tolbutamide DM02AWV Moderate Increased risk of hypoglycemia by the combination of Quinine and Tolbutamide. Type 2 diabetes mellitus [5A11] [120]
Chlorpropamide DMPHZQE Moderate Increased risk of hypoglycemia by the combination of Quinine and Chlorpropamide. Type 2 diabetes mellitus [5A11] [120]
Insulin-detemir DMOA4VW Moderate Increased risk of hypoglycemia by the combination of Quinine and Insulin-detemir. Type-1/2 diabete [5A10-5A11] [120]
Insulin degludec DMPL395 Moderate Increased risk of hypoglycemia by the combination of Quinine and Insulin degludec. Type-1/2 diabete [5A10-5A11] [120]
Elagolix DMB2C0E Moderate Increased metabolism of Quinine caused by Elagolix mediated induction of CYP450 enzyme. Uterine fibroid [2E86] [124]
Astemizole DM2HN6Q Major Decreased metabolism of Quinine caused by Astemizole mediated inhibition of CYP450 enzyme. Vasomotor/allergic rhinitis [CA08] [191]
Trimeprazine DMEMV9D Moderate Increased risk of prolong QT interval by the combination of Quinine and Trimeprazine. Vasomotor/allergic rhinitis [CA08] [173]
Procainamide DMNMXR8 Major Increased risk of prolong QT interval by the combination of Quinine and Procainamide. Ventricular tachyarrhythmia [BC71] [119]
Amiodarone DMUTEX3 Major Increased risk of prolong QT interval by the combination of Quinine and Amiodarone. Ventricular tachyarrhythmia [BC71] [119]
⏷ Show the Full List of 245 DDI Information of This Drug

Drug Inactive Ingredient(s) (DIG) and Formulation(s) of This Drug

DIG
DIG Name DIG ID PubChem CID Functional Classification
Fumaric acid E00420 444972 Acidulant; Antioxidant; Complexing agent; Flavoring agent; Solubilizing agent
Sodium lauryl sulfate E00464 3423265 Emulsifying agent; Modified-release agent; Penetration agent; Solubilizing agent; Surfactant; lubricant
Ammonia E00007 222 Alkalizing agent
Calcium stearate E00244 15324 lubricant
Carmellose sodium E00625 Not Available Disintegrant
Eisenoxyd E00585 56841934 Colorant
Ferric hydroxide oxide yellow E00539 23320441 Colorant
Ferrosoferric oxide E00231 14789 Colorant
Lactose monohydrate E00393 104938 Binding agent; Diluent; Dry powder inhaler carrier; Lyophilization aid
Magnesium stearate E00208 11177 lubricant
Potassium hydroxide E00233 14797 Alkalizing agent
Povidone E00667 Not Available Binding agent; Coating agent; Disintegrant; Film/membrane-forming agent; Solubilizing agent; Suspending agent
Propylene glycol E00040 1030 Antimicrobial preservative; Humectant; Plasticizing agent; Solvent
Saccharose E00091 5988 Binding agent; Coating agent; Cryoprotectant; Diluent; Flavoring agent; Suspending agent; Viscosity-controlling agent
Silicon dioxide E00670 Not Available Anticaking agent; Opacifying agent; Viscosity-controlling agent
Sodium alginate E00671 Not Available Binding agent; Disintegrant; Suspending agent; Viscosity-controlling agent
Talc E00520 16211421 Anticaking agent; Diluent; Glidant; lubricant
Titanium dioxide E00322 26042 Coating agent; Colorant; Opacifying agent
Triacetin E00080 5541 Humectant; Plasticizing agent; Solvent
Zinc stearate E00209 11178 lubricant
⏷ Show the Full List of 20 Pharmaceutical Excipients of This Drug
Pharmaceutical Formulation
Formulation Name Drug Dosage Dosage Form Route
Quinine 300 mg tablet 300 mg Extended Release Oral Tablet Oral
Quinine 324 mg capsule 324 mg Oral Capsule Oral
Quinine 324 mg tablet 324 mg Extended Release Oral Tablet Oral
Quinine 200 mg tablet 200 mg Oral Tablet Oral
Quinine 300 mg tablet 300 mg Oral Tablet Oral
Jump to Detail Pharmaceutical Formulation Page of This Drug

References

1 URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Ligand id: 2510).
2 FDA Approved Drug Products from FDA Official Website. 2009. Application Number: (NDA) 021799.
3 FDA approval: ado-trastuzumab emtansine for the treatment of patients with HER2-positive metastatic breast cancer. Clin Cancer Res. 2014 Sep 1;20(17):4436-41.
4 BDDCS applied to over 900 drugs
5 An FDA phase I clinical trial of quinacrine sterilization (QS). Int J Gynaecol Obstet. 2003 Oct;83 Suppl 2:S45-9.
6 Trend Analysis of a Database of Intravenous Pharmacokinetic Parameters in Humans for 1352 Drug Compounds
7 Estimating the safe starting dose in phase I clinical trials and no observed effect level based on QSAR modeling of the human maximum recommended daily dose
8 Drugs@FDA. U.S. Food and Drug Administration. U.S. Department of Health & Human Services.
9 The Transporter Classification Database (TCDB): recent advances. Nucleic Acids Res. 2016 Jan 4;44(D1):D372-9. (ID: 2.A.22.3.1)
10 Novel membrane transporter OCTN1 mediates multispecific, bidirectional, and pH-dependent transport of organic cations. J Pharmacol Exp Ther. 1999 May;289(2):768-73.
11 Na(+)-dependent carnitine transport by organic cation transporter (OCTN2): its pharmacological and toxicological relevance. J Pharmacol Exp Ther. 1999 Nov;291(2):778-84.
12 Comparison of type I and type II organic cation transport by organic cation transporters and organic anion-transporting polypeptides. J Pharmacol Exp Ther. 2001 Jul;298(1):110-5.
13 Cloning and characterization of two human polyspecific organic cation transporters. DNA Cell Biol. 1997 Jul;16(7):871-81.
14 Mammalian drug efflux transporters of the ATP binding cassette (ABC) family in multidrug resistance: A review of the past decade. Cancer Lett. 2016 Jan 1;370(1):153-64.
15 Quinine induced simvastatin toxicity through cytochrome inhibition - a case report. BMC Geriatr. 2016 Oct 1;16(1):168.
16 Inhibition of cytochrome P450 2D6: structure-activity studies using a series of quinidine and quinine analogues. Chem Res Toxicol. 2003 Apr;16(4):450-9.
17 Identification of human cytochrome P450 isoforms involved in the 3-hydroxylation of quinine by human live microsomes and nine recombinant human cytochromes P450. J Pharmacol Exp Ther. 1996 Dec;279(3):1327-34.
18 Organic anion-transporting polypeptide B (OATP-B) and its functional comparison with three other OATPs of human liver. Gastroenterology. 2001 Feb;120(2):525-33.
19 The roles of cytochrome P450 3A4 and 1A2 in the 3-hydroxylation of quinine in vivo. Clin Pharmacol Ther. 1999 Nov;66(5):454-60.
20 Drug Interactions Flockhart Table
21 Role of cytochrome P450 2C8 in drug metabolism and interactions. Pharmacol Rev. 2016 Jan;68(1):168-241.
22 Expression levels and activation of a PXR variant are directly related to drug resistance in osteosarcoma cell lines. Cancer. 2007 Mar 1;109(5):957-65.
23 Contribution of human hepatic cytochrome P450 isoforms to regioselective hydroxylation of steroid hormones. Xenobiotica. 1998 Jun;28(6):539-47.
24 Comprehensive evaluation of tamoxifen sequential biotransformation by the human cytochrome P450 system in vitro: prominent roles for CYP3A and CYP2D6. J Pharmacol Exp Ther. 2004 Sep;310(3):1062-75.
25 Isoform-specific regulation of cytochromes P450 expression by estradiol and progesterone. Drug Metab Dispos. 2013 Feb;41(2):263-9.
26 Metabolic interactions between acetaminophen (paracetamol) and two flavonoids, luteolin and quercetin, through in-vitro inhibition studies. J Pharm Pharmacol. 2017 Dec;69(12):1762-1772.
27 Potent mechanism-based inhibition of CYP3A4 by imatinib explains its liability to interact with CYP3A4 substrates. Br J Pharmacol. 2012 Apr;165(8):2787-98.
28 Effects of morin on the pharmacokinetics of etoposide in rats. Biopharm Drug Dispos. 2007 Apr;28(3):151-6.
29 The metabolism of zidovudine by human liver microsomes in vitro: formation of 3'-amino-3'-deoxythymidine. Biochem Pharmacol. 1994 Jul 19;48(2):267-76.
30 Substrates, inducers, inhibitors and structure-activity relationships of human Cytochrome P450 2C9 and implications in drug development. Curr Med Chem. 2009;16(27):3480-675.
31 Roles of cytochromes P450 1A2, 2A6, and 2C8 in 5-fluorouracil formation from tegafur, an anticancer prodrug, in human liver microsomes. Drug Metab Dispos. 2000 Dec;28(12):1457-63.
32 Effects of polyunsaturated fatty acids on prostaglandin synthesis and cyclooxygenase-mediated DNA adduct formation by heterocyclic aromatic amines in human adenocarcinoma colon cells. Mol Carcinog. 2004 Jul;40(3):180-8.
33 Endoxifen and other metabolites of tamoxifen inhibit human hydroxysteroid sulfotransferase 2A1 (hSULT2A1). Drug Metab Dispos. 2014 Nov;42(11):1843-50.
34 Cytochrome P450 1A2 (CYP1A2) activity and risk factors for breast cancer: a cross-sectional study. Breast Cancer Res. 2004;6(4):R352-65.
35 PharmGKB summary: pathways of acetaminophen metabolism at the therapeutic versus toxic doses. Pharmacogenet Genomics. 2015 Aug;25(8):416-26.
36 The effect of apigenin on pharmacokinetics of imatinib and its metabolite N-desmethyl imatinib in rats. Biomed Res Int. 2013;2013:789184.
37 The influence of metabolic gene polymorphisms on urinary 1-hydroxypyrene concentrations in Chinese coke oven workers. Sci Total Environ. 2007 Aug 1;381(1-3):38-46.
38 Identification of P450 enzymes involved in metabolism of verapamil in humans. Naunyn Schmiedebergs Arch Pharmacol. 1993 Sep;348(3):332-7.
39 Metabolism and metabolic inhibition of xanthotoxol in human liver microsomes. Evid Based Complement Alternat Med. 2016;2016:5416509.
40 Inhibitory effects of anticancer drugs on dextromethorphan-O-demethylase activity in human liver microsomes. Cancer Chemother Pharmacol. 1993;32(6):491-5.
41 Effect of genetic polymorphism on the metabolism of endogenous neuroactive substances, progesterone and p-tyramine, catalyzed by CYP2D6. Brain Res Mol Brain Res. 2004 Oct 22;129(1-2):117-23.
42 CYP2D6 polymorphisms and tamoxifen metabolism: clinical relevance. Curr Oncol Rep. 2010 Jan;12(1):7-15.
43 Effects of propofol on human hepatic microsomal cytochrome P450 activities. Xenobiotica. 1998 Sep;28(9):845-53.
44 Pharmacogenetics of schizophrenia. Am J Med Genet. 2000 Spring;97(1):98-106.
45 Roles of CYP2A6 and CYP2B6 in nicotine C-oxidation by human liver microsomes. Arch Toxicol. 1999 Mar;73(2):65-70.
46 Structure-activity relationship for human cytochrome P450 substrates and inhibitors. Drug Metab Rev. 2002 Feb-May;34(1-2):69-82.
47 Bioactivation of the tricyclic antidepressant amitriptyline and its metabolite nortriptyline to arene oxide intermediates in human liver microsomes and recombinant P450s. Chem Biol Interact. 2008 May 9;173(1):59-67.
48 Drug related genetic polymorphisms affecting adverse reactions to methotrexate, vinblastine, doxorubicin and cisplatin in patients with urothelial cancer. J Urol. 2008 Dec;180(6):2389-95.
49 Human prostate CYP3A5: identification of a unique 5'-untranslated sequence and characterization of purified recombinant protein. Biochem Biophys Res Commun. 1999 Jul 14;260(3):676-81.
50 Polymorphisms in cytochrome P4503A5 (CYP3A5) may be associated with race and tumor characteristics, but not metabolism and side effects of tamoxifen in breast cancer patients. Cancer Lett. 2005 Jan 10;217(1):61-72.
51 Induction of hepatic CYP2E1 by a subtoxic dose of acetaminophen in rats: increase in dichloromethane metabolism and carboxyhemoglobin elevation. Drug Metab Dispos. 2007 Oct;35(10):1754-8.
52 Urinary 6 beta-hydroxycortisol excretion in rheumatoid arthritis. Br J Rheumatol. 1997 Jan;36(1):54-8.
53 Clinical pharmacokinetics of imatinib. Clin Pharmacokinet. 2005;44(9):879-94.
54 Kinetics and regulation of cytochrome P450-mediated etoposide metabolism. Drug Metab Dispos. 2004 Sep;32(9):993-1000.
55 Differential mechanism-based inhibition of CYP3A4 and CYP3A5 by verapamil. Drug Metab Dispos. 2005 May;33(5):664-71.
56 The role of cytochrome P450 3A (CYP3A) isoform(s) in oxidative metabolism of testosterone and benzphetamine in human adult and fetal liver. J Steroid Biochem Mol Biol. 1993 Jan;44(1):61-7.
57 Summary of information on human CYP enzymes: human P450 metabolism data. Drug Metab Rev. 2002 Feb-May;34(1-2):83-448.
58 Prediction of cytochrome P450 3A inhibition by verapamil enantiomers and their metabolites. Drug Metab Dispos. 2004 Feb;32(2):259-66.
59 The role of human cytochrome P450 enzymes in the formation of 2-hydroxymetronidazole: CYP2A6 is the high affinity (low Km) catalyst. Drug Metab Dispos. 2013 Sep;41(9):1686-94.
60 Drug Development and Drug Interactions: Table of Substrates, Inhibitors and Inducers.
61 Differential expression and function of CYP2C isoforms in human intestine and liver. Pharmacogenetics. 2003 Sep;13(9):565-75.
62 Analysis of human cytochrome P450 2C8 substrate specificity using a substrate pharmacophore and site-directed mutants. Biochemistry. 2004 Dec 14;43(49):15379-92.
63 Interaction of sorafenib and cytochrome P450 isoenzymes in patients with advanced melanoma: a phase I/II pharmacokinetic interaction study. Cancer Chemother Pharmacol. 2011 Nov;68(5):1111-8.
64 PharmGKB summary: mycophenolic acid pathway. Pharmacogenet Genomics. 2014 Jan;24(1):73-9.
65 Possible involvement of multiple human cytochrome P450 isoforms in the liver metabolism of propofol. Br J Anaesth. 1998 Jun;80(6):788-95.
66 Influence of CYP2C8 polymorphisms on the hydroxylation metabolism of paclitaxel, repaglinide and ibuprofen enantiomers in vitro. Biopharm Drug Dispos. 2013 Jul;34(5):278-87.
67 Progesterone and testosterone hydroxylation by cytochromes P450 2C19, 2C9, and 3A4 in human liver microsomes. Arch Biochem Biophys. 1997 Oct 1;346(1):161-9.
68 Tamoxifen inhibits cytochrome P450 2C9 activity in breast cancer patients. J Chemother. 2006 Aug;18(4):421-4.
69 Characterization of the oxidative metabolites of 17beta-estradiol and estrone formed by 15 selectively expressed human cytochrome p450 isoforms. Endocrinology. 2003 Aug;144(8):3382-98.
70 Drug-drug interactions with imatinib: an observational study. Medicine (Baltimore). 2016 Oct;95(40):e5076.
71 Drug interactions with calcium channel blockers: possible involvement of metabolite-intermediate complexation with CYP3A. Drug Metab Dispos. 2000 Feb;28(2):125-30.
72 New insights into the structural features and functional relevance of human cytochrome P450 2C9. Part I. Curr Drug Metab. 2009 Dec;10(10):1075-126.
73 A potential role for the estrogen-metabolizing cytochrome P450 enzymes in human breast carcinogenesis. Breast Cancer Res Treat. 2003 Dec;82(3):191-7.
74 A mechanistic approach to antiepileptic drug interactions. Ann Pharmacother. 1998 May;32(5):554-63.
75 High-dose rabeprazole/amoxicillin therapy as the second-line regimen after failure to eradicate H. pylori by triple therapy with the usual doses of a proton pump inhibitor, clarithromycin and amoxicillin. Hepatogastroenterology. 2003 Nov-Dec;50(54):2274-8.
76 Cytochrome P450 pharmacogenetics and cancer. Oncogene. 2006 Mar 13;25(11):1679-91.
77 CYP2C19*17 is associated with decreased breast cancer risk. Breast Cancer Res Treat. 2009 May;115(2):391-6.
78 Cytochromes of the P450 2C subfamily are the major enzymes involved in the O-demethylation of verapamil in humans. Naunyn Schmiedebergs Arch Pharmacol. 1995 Dec;353(1):116-21.
79 Diclofenac and its derivatives as tools for studying human cytochromes P450 active sites: particular efficiency and regioselectivity of P450 2Cs. Biochemistry. 1999 Oct 26;38(43):14264-70.
80 Human intestinal transporter database: QSAR modeling and virtual profiling of drug uptake, efflux and interactions. Pharm Res. 2013 Apr;30(4):996-1007.
81 MDR1 (ABCB1) G1199A (Ser400Asn) polymorphism alters transepithelial permeability and sensitivity to anticancer agents. Cancer Chemother Pharmacol. 2009 Jun;64(1):183-8.
82 Folate transporter expression decreases in the human placenta throughout pregnancy and in pre-eclampsia. Pregnancy Hypertens. 2012 Apr;2(2):123-31.
83 Comparative studies on in vitro methods for evaluating in vivo function of MDR1 P-glycoprotein. Pharm Res. 2001 Dec;18(12):1660-8.
84 Antiestrogens and steroid hormones: substrates of the human P-glycoprotein. Biochem Pharmacol. 1994 Jul 19;48(2):287-92.
85 Association of genetic polymorphisms in the influx transporter SLCO1B3 and the efflux transporter ABCB1 with imatinib pharmacokinetics in patients with chronic myeloid leukemia. Ther Drug Monit. 2011 Apr;33(2):244-50.
86 Are organic cation transporters capable of transporting prostaglandins? Naunyn Schmiedebergs Arch Pharmacol. 2005 Aug;372(2):125-30.
87 Cisplatin nephrotoxicity is critically mediated via the human organic cation transporter 2. Am J Pathol. 2005 Dec;167(6):1477-84.
88 Relevance of copper transporter 1 and organic cation transporters 1-3 for oxaliplatin uptake and drug resistance in colorectal cancer cells. Metallomics. 2018 Mar 1;10(3):414-425.
89 Differential pharmacological in vitro properties of organic cation transporters and regional distribution in rat brain. Neuropharmacology. 2006 Jun;50(8):941-52.
90 Influx Transport of Cationic Drug at the Blood-Retinal Barrier: Impact on the Retinal Delivery of Neuroprotectants. Biol Pharm Bull. 2017;40(8):1139-1145.
91 The organic cation transporters (OCT1, OCT2, EMT) and the plasma membrane monoamine transporter (PMAT) show differential distribution and cyclic expression pattern in human endometrium and early pregnancy decidua. Mol Reprod Dev. 2007 Oct;74(10):1303-11.
92 Metformin is a superior substrate for renal organic cation transporter OCT2 rather than hepatic OCT1. Drug Metab Pharmacokinet. 2005 Oct;20(5):379-86.
93 A species difference in the transport activities of H2 receptor antagonists by rat and human renal organic anion and cation transporters. J Pharmacol Exp Ther. 2005 Oct;315(1):337-45.
94 Elevated systemic elimination of cimetidine in rats with acute biliary obstruction: the role of renal organic cation transporter OCT2. Drug Metab Pharmacokinet. 2010;25(4):328-34.
95 Cisplatin and oxaliplatin, but not carboplatin and nedaplatin, are substrates for human organic cation transporters (SLC22A1-3 and multidrug and toxin extrusion family). J Pharmacol Exp Ther. 2006 Nov;319(2):879-86.
96 Pharmacologic markers and predictors of responses to imatinib therapy in patients with chronic myeloid leukemia. Leuk Lymphoma. 2008 Apr;49(4):639-42.
97 Organic cation transporters are determinants of oxaliplatin cytotoxicity. Cancer Res. 2006 Sep 1;66(17):8847-57.
98 Implications of genetic polymorphisms in drug transporters for pharmacotherapy. Cancer Lett. 2006 Mar 8;234(1):4-33.
99 Upregulation of histone acetylation reverses organic anion transporter 2 repression and enhances 5-fluorouracil sensitivity in hepatocellular carcinoma
100 Organic cation transporters and their pharmacokinetic and pharmacodynamic consequences. Drug Metab Pharmacokinet. 2008;23(4):243-53.
101 Genetic variations of the SLC22A5 gene in the Chinese and Indian populations of Singapore. Drug Metab Pharmacokinet. 2010;25(1):112-9.
102 Multiple SLC and ABC Transporters Contribute to the Placental Transfer of Entecavir. Drug Metab Dispos. 2017 Mar;45(3):269-278.
103 Colistin is substrate of the carnitine/organic cation transporter 2 (OCTN2, SLC22A5). Drug Metab Dispos. 2017 Dec;45(12):1240-1244.
104 Novel organic cation transporter 2-mediated carnitine uptake in placental choriocarcinoma (BeWo) cells. J Pharmacol Exp Ther. 2005 Jan;312(1):192-8.
105 Mutations affecting GABAergic signaling in seizures and epilepsy. Pflugers Arch. 2010 Jul;460(2):505-23.
106 Transport of ipratropium, an anti-chronic obstructive pulmonary disease drug, is mediated by organic cation/carnitine transporters in human bronchial epithelial cells: implications for carrier-mediated pulmonary absorption. Mol Pharm. 2010 Feb 1;7(1):187-95.
107 Genetic deficiency of carnitine/organic cation transporter 2 (slc22a5) is associated with altered tissue distribution of its substrate pyrilamine in mice. Biopharm Drug Dispos. 2009 Dec;30(9):495-507.
108 Cloning and functional characterization of a novel up-regulator, cartregulin, of carnitine transporter, OCTN2. Arch Biochem Biophys. 2006 Aug 1;452(1):29-37.
109 OCTN1 Is a High-Affinity Carrier of Nucleoside Analogues. Cancer Res. 2017 Apr 15;77(8):2102-2111.
110 Spontaneous development of intestinal and colonic atrophy and inflammation in the carnitine-deficient jvs (OCTN2(-/-)) mice. Mol Genet Metab. 2007 Dec;92(4):315-24.
111 Effects of genetic variation in the novel organic cation transporter, OCTN1, on the renal clearance of gabapentin. Clin Pharmacol Ther. 2008 Mar;83(3):416-21.
112 Functional effects of protein sequence polymorphisms in the organic cation/ergothioneine transporter OCTN1 (SLC22A4). Pharmacogenet Genomics. 2007 Sep;17(9):773-82.
113 Interpreting metabolomic profiles using unbiased pathway models. PLoS Comput Biol. 2010 Feb 26;6(2):e1000692.
114 Deletion of the betaine-GABA transporter (BGT1; slc6a12) gene does not affect seizure thresholds of adult mice. Epilepsy Res. 2011 Jun;95(1-2):70-81.
115 Barucainide, a novel class Ib antiarrhythmic agent with a slow kinetic property: electrophysiologic observations in isolated canine and rabbit cardiac muscle. Am Heart J. 1990 May;119(5):1050-60.
116 Cerner Multum, Inc. "Australian Product Information.".
117 Abernethy DR, Wesche DL, Barbey JT, et al. "Stereoselective halofantrine disposition and effect: concentration-related QTc prolongation." Br J Clin Pharmacol 51 (2001): 231-7. [PMID: 11298069]
118 Harper KM, Knapp DJ, Criswell HE, Breese GR "Vasopressin and alcohol: A multifaceted relationship." Psychopharmacology (Berl) 235 (2018): 3363-79. [PMID: 32936259]
119 Canadian Pharmacists Association.
120 Abad S, Moachon L, Blanche P, Bavoux F, Sicard D, Salmon-Ceron D "Possible interaction between glicazide, fluconazole and sulfamethoxazole resulting in severe hypoglycaemia." Br J Clin Pharmacol 52 (2001): 456-7. [PMID: 11678792]
121 Asplund K, Wiholm BE, Lithner F "Glibenclamide-associated hypoglycaemia: a report on 57 cases." Diabetologia 24 (1983): 412-7. [PMID: 6411511]
122 Product Information. Tibsovo (ivosidenib). Agios Pharmaceuticals, Cambridge, MA.
123 Multum Information Services, Inc. Expert Review Panel.
124 Fabre C, Criddle J, Nolder D, Klein JL "Recrudescence of imported falciparum malaria after quinine therapy: potential drug interaction with phenytoin." Trans R Soc Trop Med Hyg 99 (2005): 871-3. [PMID: 16099004]
125 Product Information. Xospata (gilteritinib). Astellas Pharma US, Inc, Deerfield, IL.
126 Product Information. Reminyl (galantamine) Janssen Pharmaceuticals, Titusville, NJ.
127 Product Information. Aricept (donepezil). Pfizer US Pharmaceuticals, New York, NY.
128 Cerner Multum, Inc. "UK Summary of Product Characteristics.".
129 Product Information. Sirturo (bedaquiline). Janssen Pharmaceuticals, Titusville, NJ.
130 Product Information. Arcapta Neohaler (indacaterol). Novartis Pharmaceuticals, East Hanover, NJ.
131 Bengtsson B, Fagerstrom PO "Extrapulmonary effects of terbutaline during prolonged administration." Clin Pharmacol Ther 31 (1982): 726-32. [PMID: 7042176]
132 Ball P "Quinolone-induced QT interval prolongation: a not-so-unexpected class effect." J Antimicrob Chemother 45 (2000): 557-9. [PMID: 10797074]
133 Mirghani RA, Ericsson O, Tybring G, Gustafsson LL, Bertilsson L "Quinine 3-hydroxylation as a biomarker reaction for the activity of CYP3A4 in man." Eur J Clin Pharmacol 59 (2003): 23-8. [PMID: 12743670]
134 Zhao XJ, Ishizaki T "A further interaction study of quinine with clinically important drugs by human liver microsomes: determinations of inhibition constant (K-i) and type of inhibition." Eur J Drug Metab Pharm 24 (1999): 272-8. [PMID: 10716067]
135 Adachi Y, Suzuki H, Sugiyama Y "Quantitative evaluation of the function of small intestinal P-glycoprotein: comparative studies between in Situ and in Vivo." Pharm Res 20 (2003): 1163-9. [PMID: 12948013]
136 Product Information. Talzenna (talazoparib). Pfizer U.S. Pharmaceuticals Group, New York, NY.
137 Product Information. Daurismo (glasdegib). Pfizer U.S. Pharmaceuticals Group, New York, NY.
138 Product Information. Dificid (fidaxomicin). Optimer Pharmaceuticals, San Diego, CA.
139 Hanci V, Aydin M, Yurtlu BS, et.al "Anesthesia induction with sevoflurane and propofol: evaluation of P-wave dispersion, QT and corrected QT intervals." Kaohsiung J Med Sci 26 (2010): 470-7. [PMID: 20837343]
140 Product Information. Lamprene (clofazimine). Novartis Pharmaceuticals, East Hanover, NJ.
141 Product Information. Xarelto (rivaroxaban). Bayer Inc, Toronto, IA.
142 Product Information. Cymbalta (duloxetine). Lilly, Eli and Company, Indianapolis, IN.
143 Antonelli D, Atar S, Freedberg NA, Rosenfeld T "Torsade de pointes in patients on chronic amiodarone treatment: contributing factors and drug interactions." Isr Med Assoc J 7 (2005): 163-5. [PMID: 15792261]
144 Product Information. Austedo (deutetrabenazine). Teva Pharmaceuticals USA, North Wales, PA.
145 Product Information. Ingrezza (valbenazine). Neurocrine Biosciences, Inc., San Diego, CA.
146 Amabeoku GJ, Chikuni O, Akino C, Mutetwa S "Pharmacokinetic interaction of single doses of quinine and carbamazepine, phenobarbitone and phenytoin in healthy volunteers." East Afr Med J 70 (1993): 90-3. [PMID: 8513749]
147 Brynne N, Svanstrom C, AbergWistedt A, Hallen B, Bertilsson L "Fluoxetine inhibits the metabolism of tolterodin-pharmacokinetic implications and proposed clinical relevance." Br J Clin Pharmacol 48 (1999): 553-63. [PMID: 10583026]
148 Product Information. Enablex (darifenacin). Novartis Pharmaceuticals, East Hanover, NJ.
149 Product Information. Qualaquin (quinine). AR Scientific Inc, Philadelphia, PA.
150 Product Information. Adcetris (brentuximab vedotin). Seattle Genetics Inc, Bothell, WA.
151 Product Information. Rukobia (fostemsavir). ViiV Healthcare, Research Triangle Park, NC.
152 Product Information. Sustiva (efavirenz). DuPont Pharmaceuticals, Wilmington, DE.
153 Anson BD, Weaver JG, Ackerman MJ, et al. "Blockade of HERG channels by HIV protease inhibitors." Lancet 365 (2005): 682-686. [PMID: 15721475]
154 Kumar GN, Rodrigues AD, Buko AM, Denissen JF "Cytochrome p450-mediated metabolism of the HIV-1 protease inhibitor ritonavir (ABT-538) in human liver microsomes." J Pharmacol Exp Ther 277 (1996): 423-31. [PMID: 8613951]
155 Product Information. Samsca (tolvaptan). Otsuka American Pharmaceuticals Inc, Rockville, MD.
156 Product Information. Orladeyo (berotralstat). BioCryst Pharmaceuticals Inc, Durham, NC.
157 Hill AG, Parry BR "Hypokalaemia following bowel cleansing with sodium phosphate." N Z Med J 109 (1996): 347. [PMID: 8862361]
158 Product Information. Movantik (naloxegol). Astra-Zeneca Pharmaceuticals, Wilmington, DE.
159 Product Information. Xalkori (crizotinib). Pfizer U.S. Pharmaceuticals Group, New York, NY.
160 Product Information. Alunbrig (brigatinib). Ariad Pharmaceuticals Inc, Cambridge, MA.
161 Blakely KM, Drucker AM, Rosen CF "Drug-induced photosensitivity-an update: Culprit drugs, prevention and management." Drug Saf 42 (2019): 827-47. [PMID: 30888626]
162 Product Information. Tagrisso (osimertinib). Astra-Zeneca Pharmaceuticals, Wilmington, DE.
163 Product Information. Zydelig (idelalisib). Gilead Sciences, Foster City, CA.
164 Ohnishi K, Yoshida H, Shigeno K, et al. "Prolongation of the QT interval and ventricular tachycardia in patients treated with arsenic trioxide for acute promyelocytic leukemia." Ann Intern Med 133 (2000): 881-5. [PMID: 11103058]
165 Product Information. Braftovi (encorafenib). Array BioPharma Inc., Boulder, CO.
166 Product Information. Ubrelvy (ubrogepant). Allergan Inc, Irvine, CA.
167 Product Information. Exjade (deferasirox). Novartis Pharmaceuticals, East Hanover, NJ.
168 Product Information. Farydak (panobinostat). Novartis Pharmaceuticals, East Hanover, NJ.
169 Product Information. Zeposia (ozanimod). Celgene Corporation, Summit, NJ.
170 Product Information. Sprycel (dasatinib). Bristol-Myers Squibb, Princeton, NJ.
171 Doherty MM, Charman WN "The mucosa of the small intestine: how clinically relevant as an organ of drug metabolism?" Clin Pharmacokinet 41 (2002): 235-53. [PMID: 11978143]
172 Product Information. Zejula (niraparib). Tesaro Inc., Waltham, MA.
173 Iannini PB "Cardiotoxicity of macrolides, ketolides and fluoroquinolones that prolong the QTc interval." Expert Opin Drug Saf 1 (2002): 121-8. [PMID: 12904146]
174 Agencia Espaola de Medicamentos y Productos Sanitarios Healthcare "Centro de informacion online de medicamentos de la AEMPS - CIMA.".
175 Product Information. Nuplazid (pimavanserin). Accelis Pharma, East Windsor, NJ.
176 Product Information. Xeglyze (abametapir topical). Dr. Reddy's Laboratories Inc, Upper Saddle River, NJ.
177 Product Information. Macrilen (macimorelin). Aeterna Zentaris, Charleston, SC.
178 Product Information. Xenleta (lefamulin). Nabriva Therapeutics US, Inc., King of Prussia, PA.
179 Product Information. Orgovyx (relugolix). Myovant Sciences, Inc., Brisbane, CA.
180 Product Information. Rapaflo (silodosin). Watson Pharmaceuticals, Corona, CA.
181 Product Information. Prograf (tacrolimus). Fujisawa, Deerfield, IL.
182 Ansari SR, Chopra N "Gatifloxacin and Prolonged QT Interval." Am J Med Sci 327 (2004): 55-6. [PMID: 14722399]
183 Abernethy DR, Greenblatt DJ, Steel K, Shader RI "Impairment of hepatic drug oxidation by propoxyphene." Ann Intern Med 97 (1982): 223-4. [PMID: 7103282]
184 Product Information. Abilify (aripiprazole). Bristol-Myers Squibb, Princeton, NJ.
185 Product Information. Barhemsys (amisulpride). Acacia Pharma, Inc, Indianapolis, IN.
186 Aronson JK, Grahame-Smith DG "Clinical pharmacology: adverse drug interactions." Br Med J 282 (1981): 288-91. [PMID: 6779990]
187 Celiker A, Tokel K, Cil E, Ozkutlu S, Ozme S "Adenosine induced torsades de pointes in a child with congenital long QT syndrome." Pacing Clin Electrophysiol 17 (1994): 1814-7. [PMID: 7838793]
188 Product Information. Tavalisse (fostamatinib). Rigel Pharmaceuticals, South San Francisco, CA.
189 EMA. European Medicines Agency. European Union "EMA - List of medicines under additional monitoring.".
190 Goto M, Sato M, Kitzazawa H, et.al "Papaverine-induced QT interval prolongation and ventricular fibrillation in a patient with a history of drug-induced QT prolongation." Intern Med 53 (2014): 1629-31. [PMID: 25088875]
191 Martin ES, Rogalski K, Black JN "Quinine may trigger torsades de pointes during astemizole therapy." Pacing Clin Electrophysiol 20 (1997): 2024-5. [PMID: 9272545]